Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021047 · ClinicalTrials.gov registry record · Phase 1
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00021047 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC).
The verdict
NCT00021047, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin, carboplatin, and capecitabine in treating patients who have unresectable locally advanced, metastatic, or recurrent solid tumor.
Interventions
- DRUG carboplatin
- DRUG capecitabine
- DRUG epirubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2004-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021047
The ClinicalTrials.gov registry entry for NCT00021047 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00021047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021047 about?
NCT00021047 is a clinical study titled "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin, carboplatin, and capecitabine in treating pat...
What is the current status of trial NCT00021047?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-07. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00021047?
The interventions under investigation include: carboplatin (DRUG), capecitabine (DRUG), epirubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00021047?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.